U.S. Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,447.00-34.00 (-0.76%)
At close: 4:36PM BST
Full screen
Previous Close4,481.00
Bid4,352.00 x 10000
Ask4,548.00 x 30000
Day's Range4,418.50 - 4,480.50
52 Week Range3,996.00 - 5,520.00
Avg. Volume2,174,313
Market Cap56.29B
PE Ratio (TTM)16.66
Earnings DateN/A
Dividend & Yield2.79 (4.93%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
    Zacks6 hours ago

    AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

    AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.

  • Financial Times7 hours ago

    [$$] Small-cap focus: UK biotechs seek to prosper in immunotherapy

    While AstraZeneca has suffered a serious setback in the hot field of cancer immunotherapy, a host of comparative minnows, undeterred, are pressing ahead with allied technologies that promise millions in ...

  • Reuters23 hours ago

    FDA expands use of AstraZeneca/Merck ovarian cancer drug

    The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.